ArticlePLoS neglected tropical diseases2021
A novel mechanism of streptomycin resistance in Yersinia pestis: Mutation in the rpsL gene.
Article in PLoS neglected tropical diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 46 citations in OpenAlex.
- Positive epistasis among ribosomal mutations drives high-level streptomycin resistance inApplied and environmental microbiology · 2026Article
- Protective outcomes of high-affinity monoclonal antibodies against drug-resistant plague strains.Frontiers in immunology · 2026Article
- Combating Drug-Resistant Tuberculosis: Advancements in Diagnostics and Therapeutics.Pulmonary medicine · 2026Review
- A Novel, Broad-Spectrum, Virulent Bacteriophage TargetingPathogens (Basel, Switzerland) · 2025Article
- Transboundary Diseases and One Health Approach Implications for Global Health Threats, with Particular Interest in Conservation and Bioterrorism.Pathogens (Basel, Switzerland) · 2025Review
- Ribosome deficiency inducesmBio · 2025Article
- Nanopore-based targeted sequencing (NTS) for drug-resistant tuberculosis: an integrated tool for personalized treatment strategies and guidance for new drug development.BMC infectious diseases · 2025Article
- Susceptibility ofLife (Basel, Switzerland) · 2025Article
- Hotspots of genetic change in Yersinia pestis.Nature communications · 2025Article
- Based on quorum sensing: reverse effect of traditional Chinese medicine on bacterial drug resistance mechanism.Frontiers in cellular and infection microbiology · 2025Review
- Development of Effective Medical Countermeasures Against the Main Biowarfare Agents: The Importance of Antibodies.Microorganisms · 2024Review
- Inactivation of the ribosome assembly factor RimP causes streptomycin resistance and impairs motility inAntimicrobial agents and chemotherapy · 2024Article
- Phylogenetic Relationships and Evolution of the GenusViruses · 2024Article
- Deficiency in ribosome biogenesis causes streptomycin resistance and impairs motility inbioRxiv : the preprint server for biology · 2024Article
- Macrolide resistance inFrontiers in microbiology · 2024Article
- Enhance the Antimycobacterial Activity of Streptomycin with Ebselen as an Antibiotic Adjuvant Through Disrupting Redox Homeostasis.Drug design, development and therapy · 2024Article
- Two NovelViruses · 2022Article
- Applications of polymerase chain reaction-based methods for the diagnosis of plague (Review).Experimental and therapeutic medicine · 2022Review
- Transmission of Antimicrobial Resistant Yersinia pestis During a Pneumonic Plague Outbreak.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Article
- Yersinia pestis antibiotic resistance: a systematic review.Osong public health and research perspectives · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Streptomycin is considered to be one of the effective antibiotics for the treatment of plague. In order to investigate the streptomycin resistance of Y. pestis in China, we evaluated streptomycin susceptibility of 536 Y. pestis strains in China in vitro using the minimal inhibitory concentration (MIC) and screened streptomycin resistance-associated genes (strA and strB) by PCR method. A clinical Y. pestis isolate (S19960127) exhibited high-level resistance to streptomycin (the MIC was 4,096 mg/L). The strain (biovar antiqua) was isolated from a pneumonic plague outbreak in 1996 in Tibet Autonomous Region, China, belonging to the Marmota himalayana Qinghai-Tibet Plateau plague focus. In contrast to previously reported streptomycin resistance mediated by conjugative plasmids, the genome sequencing and allelic replacement experiments demonstrated that an rpsL gene (ribosomal protein S12) mutation with substitution of amino-acid 43 (K43R) was responsible for the high-level resistance to streptomycin in strain S19960127, which is consistent with the mutation reported in some streptomycin-resistant Mycobacterium tuberculosis strains. Streptomycin is used as the first-line treatment against plague in many countries. The emergence of streptomycin resistance in Y. pestis represents a critical public health problem. So streptomycin susceptibility monitoring of Y. pestis isolates should not only include plasmid-mediated resistance but also include the ribosomal protein S12 gene (rpsL) mutation, especially when treatment failure is suspected due to antibiotic resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.